Abstract
Pazopanib (PAZ) is an angiogenesis inhibitor approved for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma (STS). A relationship was reported between PAZ trough concentration (Cmin) and progression free survival (PFS) in RCC (Suttle A.B. 2015; Verheijen R.B. 2017). However, information on the exposure-efficacy relationship in sarcoma remains sparse. A PAZ Cmin threshold of 27 mg/L was determined in an exploratory study (Bellesoeur A. 2017).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have